Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Income (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Operating Income for 5 consecutive years, with $44.3 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 7.0% to $44.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $161.1 million through Dec 2025, up 145.14% year-over-year, with the annual reading at $161.3 million for FY2025, 145.32% up from the prior year.
  • Operating Income hit $44.3 million in Q4 2025 for Krystal Biotech, up from $41.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $44.3 million in Q4 2025 to a low of -$50.2 million in Q1 2022.
  • Historically, Operating Income has averaged -$4.8 million across 5 years, with a median of -$15.0 million in 2021.
  • Biggest five-year swings in Operating Income: crashed 249.91% in 2022 and later skyrocketed 1173.86% in 2024.
  • Year by year, Operating Income stood at -$21.9 million in 2021, then plummeted by 58.95% to -$34.8 million in 2022, then soared by 109.34% to $3.2 million in 2023, then surged by 1173.86% to $41.4 million in 2024, then grew by 7.0% to $44.3 million in 2025.
  • Business Quant data shows Operating Income for KRYS at $44.3 million in Q4 2025, $41.4 million in Q3 2025, and $39.3 million in Q2 2025.